SCHEMBL6865700

SCHEMBL6865700

O=C(O)c1ccc(C#Cc2ccccc2)c(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.49
HAO1 Q9UJM8 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.42
TTR P02766 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
P4HB P07237 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.40
SLC16A3 O15427 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
HNF4A P41235 1/20 0.40
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
PDK2 Q15119 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13103198 0.88 HAO1 (0.53) FFAR1HAO1MRGPRX4TTRFFAR4
SCHEMBL5669422 0.85 RARB (0.47) FFAR1FFAR4NPC1RAB9ARARB
SCHEMBL8506793 0.85 NOTUM (0.51) FFAR1HAO1RAB9AP4HBPDK2
SCHEMBL17672523 0.83 AR (0.42) MRGPRX4TTRP4HBRXRARXRB
SCHEMBL17672825 0.82 RARB (0.45) FFAR1MRGPRX4RARBRARGSLC16A3
Hydrochloric Acid SCHEMBL8506942 0.82 SLC9A1 (0.48) FFAR1
Hydrochloric Acid SCHEMBL8506938 0.80 FFAR1 (0.40) FFAR1HAO1FFAR4NPC1RAB9A
SCHEMBL6866180 0.80 FFAR1 (0.58) FFAR1HAO1TTRFFAR4NPC1
SCHEMBL5669139 0.79 HAO1 (0.43) FFAR1HAO1MRGPRX4FFAR4NPC1
SCHEMBL5666516 0.79 TTR (0.49) FFAR1TTRFFAR4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812252-B2 ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 US disclosed
US-20030181764-A1 Acylsulfonamide derivatives AJINOMOTO CO. INC (JP) 2003-09-25 US disclosed
EP-1316548-A1 ACYLSULFONAMIDE DERIVATIVES Ajinomoto Co., Inc. (JP) 2003-06-04 EP disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181764-A1 Acylsulfonamide derivatives DPP4, SLC5A2, GLP1R FFAR1 83/4885HAO1 3221/4885MRGPRX4 3905/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 FFAR1 169/4885HAO1 1889/4885MRGPRX4 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.